Niels van de Donk

Niels van de Donk at Amsterdam UMC is a leading multiple myeloma researcher who has contributed to the clinical development of teclistamab (BCMA x CD3) and other bispecific antibodies for relapsed/refractory myeloma. His participation in the MajesTEC-1 trial helped establish teclistamab as a novel treatment for heavily pre-treated patients. He has contributed to characterizing the immunological mechanisms and resistance patterns of BCMA-targeted bispecifics. His work spans plasma cell biology, novel drug development, and myeloma treatment optimization.